Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $58

Benzinga Newsdesk 20 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $64 to $58.

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $64 to $58.

Read at benzinga.com

← All stock news